Home › NCT04990609

EUS-RFA PANCARDINAL-1 Trial

A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosed and histologically-confirmed PDAC by biopsy
* Permanent street address
* Consent to study participation
* Axial CT scan consistent with PDAC
* No prior chemotherapy or less than 2 months of pre-operative chemotherapy for PDAC
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Exclusion Criteria:

* Male or female patients \< 18 years of age
* No permanent street address or telephone number
* Pregnant patients
* Inmates or prisoners
* Unable to provide informed consent

About the study

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.

What is being tested

• Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) (device)
• Neoadjuvant Chemotherapy (NAC) (drug)

Sponsor: The University of Texas Health Science Center, Houston · Participants: 60 · Started: Aug 13, 2021

Contact the study team

• Amatullah Alibhai, B.A., M.B.A. · Phone: 713-486-1443
• Nicole Fatheree, B.B.A. · Phone: 713-500-5669

Official record on ClinicalTrials.gov — NCT04990609

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.